Formation and Remodeling of Inositolphosphoceramide during Differentiation of *Trypanosoma cruzi* from Trypomastigote to Amastigote

Maria Laura Salto, Laura E. Bertello, Mauricio Vieira, Roberto Docampo, Silvia N. J. Moreno, and Rosa M. de Lederkremer

Laboratory of Molecular Parasitology, Department of Pathobiology and Center for Zoonoses Research, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois 61802, and CIHIDECAR, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, 1428 Buenos Aires, Argentina

Received 4 April 2003/Accepted 3 June 2003

Differentiation of *Trypanosoma cruzi* trypomastigotes to amastigotes inside myoblasts or in vitro, at low extracellular pH, in the presence of [3H]palmitic acid or [3H]inositol revealed differential labeling of inositolphosphoceramide and phosphatidylinositol, suggesting that a remodeling process takes place in both lipids. Using [3H]-labeled inositolphosphoceramide and phosphatidylinositol as substrates, we demonstrated the association of at least five enzymatic activities with the membranes of amastigotes and trypomastigotes. These pathways in *Trypanosoma cruzi* trypomastigotes inside myoblasts or in vitro, at low extracellular pH, in the presence of [3H]palmitic acid or [3H]inositol revealed differential labeling of inositolphosphoceramide and phosphatidylinositol, suggesting that a remodeling process takes place in both lipids. Using [3H]-labeled inositolphosphoceramide and phosphatidylinositol as substrates, we demonstrated the association of at least five enzymatic activities with the membranes of amastigotes and trypomastigotes. These enzymes may be acting in remodeling reactions leading to the anchor of mature glycoproteins or glycoinositolphospholipids and helping in the transformation of the plasma membrane, a necessary step in the differentiation of slender trypomastigotes to round amastigotes. Synthesis of inositolphosphoceramide and particularly of glycoinositolphospholipids was inhibited by aureobasidin A, a known inhibitor of fungal inositolphosphoceramide synthases. The antibiotic impaired the differentiation of trypomastigotes at acidic pH, as indicated by an increased appearance of intermediate forms and a decreased expression of the Ssp4 glycoprotein, a characteristic marker of amastigote forms. Aureobasidin A was also toxic to differentiating trypomastigotes at acidic pH but not to trypomastigotes maintained at neutral pH. Our data suggest that inositolphosphoceramide is implicated in *T. cruzi* differentiation and that its metabolism could provide important targets for the development of antiparasitic therapies.

*Trypanosoma cruzi* is the etiologic agent of Chagas’ disease or American trypanosomiasis. *T. cruzi* has been recognized as a significant cause of morbidity and mortality from Mexico to South America (4). Chagas’ disease remains a problem because of limited therapeutic choices and adverse reactions to the two drugs available, nifurtimox and benznidazole (4, 14). Therefore, it is important to identify enzymes and metabolic pathways in *T. cruzi* that might be potential targets for drug development. *T. cruzi* has three main developmental stages: the epimastigote, which is found in the insect vector and can be grown in axenic culture; the amastigote or intracellular form, which lives in the cytosol of nucleated cells; and the trypomastigote, which is the terminal differentiation stage in the vector (metacyclic form) or is found in the bloodstream of mammalian hosts (bloodstream form).

All life cycle stages of *T. cruzi* possess on their cell surface glycoinositolphospholipid (GIPL)-anchored glycoproteins as well as free (non-protein-linked) GIPLs (24). The inositolphospholipids (IPLs) of these anchors can possess either a glycerolipid or a ceramide. In contrast, only acylglycerophospholipids have been identified in the anchor of *T. cruzi* glycoproteins (17, 18), while diacyl- or alkylacylglycerolipids are part of the anchors of mammalian glycoproteins (5, 25, 30). Several important glycoproteins of *T. cruzi* are attached to the cell surface via a ceramide-containing anchor linked to the C terminus of the protein (24), such as the Ssp4 antigen of amastigote forms (3, 7), the unique trans-sialidase glycoprotein (2), and the mucins of metacyclic trypomastigotes (1). Interestingly, the Ssp4 of amastigotes (3) and the trans-sialidase of trypomastigotes (2) are released to the medium by an endogenous phosphatidylinositol-phospholipase C (PI-PLC). In the free GIPLs of log-phase epimastigotes, both an alklyacylglycerol (AAG), 1-O-hexadecyl-2-O-palmitoylglycerol, and ceramide have been identified (11), whereas only ceramide was found in the related lipoprotein phosphoglycan of stationary-phase epimastigotes (12). The two major ceramides in the lipoprotein phosphoglycan are palmitoylsphinganine and lignoceroylsphinganine. However, no nonglyceric acid is present in the radioactive precursor inositolphosphoceramides (IPC's), nor in the cold samples obtained from *T. cruzi* (8). The biosynthetic pathway for the introduction of ceramide in the anchor of glycoproteins of *T. cruzi* is not known, but this...
lipid was also described as an anchor of glycoproteins of Saccharomyces cerevisiae (10, 16). In this organism, ceramide is introduced by a remodeling reaction (28, 32, 33) that replaces the glycerolipid with a newly synthesized ceramide (29). The variations found in the lipid moiety of T. cruzi GPIPLs suggest that a remodeling mechanism may occur here, too. This is supported by the finding that IPC is not a substrate for the first step of the biosynthesis of GPIPLs (L. E. Bertello et al., unpublished results). A detailed analysis of the IPLs and of their possible use as substrates of T. cruzi phospholipases is a necessary step for understanding the remodeling processes.

The composition of the IPLs from epimastigote (8) and trypomastigote (37) forms has been previously reported. When the lipids were labeled by incorporation of [3H]palmitic acid, IPCs accounted for 80 to 85% of the label of the total IPLs in epimastigotes and they contributed to 58% of the labeled IPLs in infective trypomastigotes.

The transformation of trypomastigotes into amastigotes occurs after invasion of mammalian cells but can also be induced in vitro by low extracellular pH (36). The glycosylphosphatidylinositol (GPI)-anchored surface glycoprotein Ssp4 was found to be a marker for the differentiation process, since it is detected with monoclonal antibodies only in recently differentiated amastigotes (3). This antigen is then progressively shed, by the action of an endogenous PI-PLC (3). The lipid moiety of the anchor of Ssp4 is the ceramide palmitoyldihydrosphingosine (PDHS), which reaches maximal concentration in the cells at 18 to 24 h of trypomastigote-to-amastigote transformation, coinciding with Ssp4 shedding (7). During this differentiation process the expression of a PI-PLC, which is able to hydrolyze either PI or IPC (31), is induced, and the enzyme associates with the plasma membrane and increases its catalytic activity (19). Taken together, these results suggest that profound changes occur in the composition of the plasma membrane during the differentiation of trypomastigotes to amastigotes. Interestingly, phosphoinositol-containing sphingolipids, such as IPC, are present in fungi and protozoa but absent in humans, and their metabolism is therefore likely to offer unique targets for antifungal (27) and antiparasitic drugs. In addition, sphingolipids such as ceramide have been proposed as intracellular mediators in various cellular responses (21, 22) and could potentially be involved in the differentiation process or in the pathogenic mechanisms of T. cruzi.

We report here that the differentiation of trypomastigotes to amastigotes in vitro or inside infected myoblasts is accompanied by the production and remodeling of IPC and PI. Evidence is provided that membranes of trypomastigotes and amastigotes possess the enzymes required for this remodeling process. We also show that aureobasidin A, a known inhibitor of yeast IPC synthase (27), inhibited the biosynthesis of IPC and GPIPLs during in vitro differentiation of trypomastigotes. The antibiotic also impaired differentiation, as shown by the large number of intermediate forms produced and by the lack of expression of the amastigote marker Ssp4.

MATERIALS AND METHODS

Cultures and metabolic labeling of T. cruzi. T. cruzi amastigotes and trypomastigotes (Y strain) were obtained from the culture medium of L1210 myoblasts as described previously (19). T. cruzi epimastigotes from the Z strain were grown at 28°C in liver infusion tryptose medium (9) supplemented with 5% newborn calf serum. Trypomastigotes were induced to transform into amastigotes axenically as described previously (19, 36). Briefly, trypomastigotes were washed twice with medium 199 supplemented with 3.7 g of NaHCO₃/liter and 0.4% bovine serum albumin (fraction V), pH 7.5. The cells were resuspended at a concentration of 10⁷ cells/ml in fresh medium, at either pH 7.5 or 5.0, containing [3H]palmitic acid or 2-[(3H)pro-myo-inositol and 0.4% bovine serum albumin. The medium was buffered with 20 mM 2-[N-morpholino]ethanesulfonic acid (MES; pH 5.0) or 20 mM HEPES (pH 7.5). For experiments without radiolabeled compounds (Fig. 9), the differentiation was induced in Dulbecco’s modified Eagle’s medium under the same conditions described for the use of medium 199.
Parasites were incubated at 35°C for different times, washed twice with Dulbecco’s phosphate-buffered saline, and extracted with chloroform-methanol-water (10:10:3). The extracts were dried in a Speed-Vac evaporator and further purified by partition in water–1-butanol (1:1, vol/vol). The organic phase was dried and kept at –20°C for further analysis. Aureobasidin A was dissolved in ethanol and added to the cultures in the amounts indicated in the figure legends. At a final concentration of 0.05 to 0.2%, ethanol had no significant effects on differentiation. However, concentrations of ethanol of 1% or above resulted in an increase in intermediate forms.

Chemicals. Dulbecco’s modified Eagle’s medium, Dulbecco’s phosphate-buffered saline, Hanks medium, cold fish gelatin, fetal and newborn calf sera, LeuCo, bee venom phospholipase A2 (PLA2) from Apis mellifera (1,200 U/mg of solid, 1,350 U/mg of protein), and MES were purchased from Sigma Chemical Co (St. Louis, Mo.). [3H]palmitic acid (39 Ci/mmol), 2-[3H]inoositol (2,000 Ci/mmol), and En3Hance were from NEN Life Science Products (Boston, Mass.). [3H]inositol (1 Ci/ml) or [3H]palmitic acid (5 Ci/ml) for 24 h in medium 199 containing 20% dialyzed fetal calf serum (Atlanta Biologies). Cells were washed three times with 4 ml of Hanks medium to remove excess radioactive compounds and were then infected with 5 × 10⁸ trypomastigotes. After 3 h the trypomastigotes in the supernatant were collected. Less than 1% of the added radioactivity could be detected in the collected parasites. The infected myoblasts were cultured for 6, 12, 18, 24, and 48 h. Control uninfected myoblasts were prepared in the same way. Three hours before the end of the cultivation period, 15 mM LiCl, a phosphatase inhibitor, was added to the culture medium. After incubation for the indicated times, 0.5 ml of Hanks medium and 1 ml of 0.5 M HClO₄ were added and the culture was kept at 0°C for 20 min. After centrifugation for 10 min at 1,500 × g the pellet was separated and the lipids were extracted with chloroform-methanol-concentrated hydrochloric acid (100:100:1, by volume) and analyzed by thin-layer chromatography (TLC) with solvent system A (see below).

Preparation of membrane and supernatant fractions. Amastigotes and trypomastigotes were lysed by suspension in hypotonic medium containing 0.5 mM NaHCO₃, 10 mM HEPES (pH 7.4), 1 mM EGTA, 1 mM dithiothreitol, and 10 μg of leupeptin/ml. The suspension was mixed in a vortex for 30 s, left for 15 min at 0°C, and further homogenized with a Teflon tissue homogenizer. The homogenate was then centrifuged at 37,000 × g for 12 min at 4°C. The supernatant and the pellet were stored separately at –70°C in aliquots corresponding to 10⁷ cells.

Extraction and purification of IPLs from epimastigotes. Epimastigotes at the logarithmic growth stage (2 days of culture; 2 × 10⁷ cells) were labeled with [3H]palmitic acid for 18 h as reported previously (8). Cells were freeze-dried and extracted with 2:1 (vol/vol; 20 ml) and 1:1 (vol/vol; 20 ml) mixtures of chloroform-methanol. The extracts were dried, and the inositolphosphate (IP)-containing lipids were separated from the neutral lipids by DEAE-Sephadex A25 (acelate form) column chromatography (23). Neutral lipids were eluted with 50 ml of methanol–chloroform–water (30:15:4, by volume), and acidic lipids were eluted with 50 ml of methanol–chloroform–0.8 M sodium acetate (30:15:4, by volume). The last fraction was evaporated, and salts were removed by passing them through a C₁₈ cleanup cartridge (AcuBond H; Agilent Technologies, Palo Alto, Calif.). Salts were removed with water, and IPLs were eluted with methanol. Further purification was achieved by column chromatography on silica gel 60 equilibrated with chloroform, with elution with a 4:1 (vol/vol) and then a 1:1 (vol/vol) mixture of chloroform-methanol.
and 108 cell equivalents of standard incubation mixture consisted of the radioactive substrate (250,000 cpm) described above were used as substrates for the subsequent experiments. The membrane fraction, suspended in 100 μl of buffer, was dissolved in chloroform-methanol (1:1, vol/vol). A control incubation of the substrate without membranes was also done. An overnight incubation with a supernatant corresponding to 108 cells/ml was incubated with 10 μCi of [3H]inositol/ml or 10 μCi of [3H]palmitic acid/ml in the presence of 5 to 20 μg of aureobasidin A/ml for different times. Differentiation in vitro was induced as described above. After incubation, lipids were extracted and analyzed by TLC.

Effect of aureobasidin A on in vitro differentiation of trypomastigotes. Trypomastigotes (10⁷ cells/ml) were incubated with 10 μCi of [3H]inositol/ml or 10 μCi of [3H]palmitic acid/ml for 90 min at 37°C. The lipids were extracted with 1-butanol (three times with 0.5 ml each) and analyzed by TLC in solvent C or D. The PLα reaction was performed in the same buffer with 2.5 mM CaCl₂ added. The samples were incubated with 25 μCi of venom PLα from A. mellifera for 2 to 4 h at 37°C. After the reaction the lipids were extracted with 1-butanol and analyzed by TLC in solvent B.

Chemical degradation. Radioactive IPC was hydrolyzed for 18 h at 70 to 78°C with HCl-methanol-water (3:29:4, by volume), and the hydrolysate was extracted with diethyl ether. The long-chain bases were analyzed by TLC in solvent E. The original lipids or the lipids isolated after PI-PLC treatment were hydrolyzed with 2.5 M NaOH in 90% methanol for 1 h at 37°C. After neutralization with 10% (vol/vol) glacial acetic acid, the lipids were extracted with 1-butanol and analyzed by TLC.

RESULTS


discussed above to 1-butanol–water partition. The radiolabeled lipids were recovered in the 1-butanol phase, which was washed with water, dried, and analyzed by TLC in solvent B.

Electron microscopy. Trypomastigotes were induced to differentiate at pH 5.0, as described above. Controls remained at pH 7.5. After 5 h, parasites were washed with buffers at the corresponding pH and fixed in Karnovsky’s solution. Fixed samples were washed with 0.1 M cacodylate buffer, pH 7.2, and postfixed in 1% osmium tetroxide and 1.5% potassium ferrocyanide at room temperature in the same buffer. After washing in 10% ethanol, samples were dehydrated by incubations with increasing ethanol concentrations (25, 50, 75, and 100%) at room temperature. Infiltration and embedding were done in Epon, and blocks were polymerized at 60°C. Ultrathin sections were collected on copper grids, stained with uranyl acetate and lead citrate, and observed by transmission electron microscopy.

Synthesis of IPC during trypomastigote-to-amastigote differentiation in infected myoblasts. In order to investigate the synthesis of IPC during the trypomastigote-to-amastigote differentiation inside mammalian cells, we labeled L₆E₉ myoblasts with either [3H]palmitic acid or [3H]inositol for 24 h. The myoblasts were washed to eliminate nonincorporated radioactivity and infected with trypomastigotes for 3 h. After that time, noninvading parasites were removed and IPL analysis was performed at different times postinfection.

Figure 1A shows the TLC analysis of the ³H-IPLs extracted from the control (lanes 1, 3, and 5) and infected (lanes 2, 4, and 6) cells after different incubation times (18, 24, and 48 h). All the compounds with higher mobility than that of inositol were sensitive to bacterial PI-PLC treatment, indicating their IPL nature (data not shown). Compounds with somewhat lower mobility than that of PI, corresponding to IPC, were extracted from the infected cells but not from control cells after 18 h of incubation (Fig. 1A, lane 2), and their amount increased with time (Fig. 1A, lanes 4 and 6). Analysis of samples taken after 6 and 12 h of incubation did not show any difference between infected and control cells (data not shown). When these experiments were repeated using myoblasts labeled with [3H]palmitic acid instead of [3H]inositol, no radioactive IPC could be detected in either control or infected cells (Fig. 1B).
Taken together these results suggest that the inositol in the IPC is coming from \([^{3}H]\)inositol incorporated by the myoblasts, while the ceramide is probably of parasite origin.

**Synthesis of IPC during in vitro differentiation of trypomastigotes to amastigotes.** We also investigated the synthesis of IPC during the in vitro differentiation of trypomastigote to amastigote stages induced by low extracellular pH (36). As described before (19, 36), ~70% of the cells appeared rounded, as amastigotes, after 5 h at pH 5.0, while trypomastigotes were morphologically unchanged at pH 7.5. Both \([^{3}H]\)palmitic acid (Fig. 2A) and \([^{3}H]\)inositol (Fig. 2B) were incorporated into PI and IPC. Two bands corresponding to...
IPC (IPCa and IPCb) were detected that were previously identified in trypomastigotes (37), the ceramide corresponding mainly to PDHS in IPCa and palmitoylsphingosine (PS) in IPCb. Their structures were confirmed by elution of the bands from the plate shown in Fig. 2A, treatment with bacterial PI-PLC, and identification of the ceramides released by reverse-phase TLC in solvent F, as described in Materials and Methods (Fig. 3, lane 1). The ceramides released by similar treatment of epimastigote IPCs (8) were also analyzed for comparison (Fig. 3, lane 2). The major ceramide present in differentiating trypomastigotes was PDHS (Fig. 3, lane 1), as occurs in epimastigotes (Fig. 3, lane 2), with a minor amount of PS. The structure of the base was confirmed by acid methanolysis and TLC in solvent E. Dihydrosphingosine was the main base, with a minor amount of sphingosine (data not shown).

IPCb was more abundant in the [3H]inositol-labeled samples after 2 to 6 h of incubation (Fig. 2B, lanes 8, 10, and 12), whereas it was the minor component when cells were labeled with [3H]palmitic acid (Fig. 2A, lanes 2, 4, and 6). This suggests that a remodeling process is taking place in IPCb, introducing either a nonradioactive ceramide or a nonradioactive fatty acid, which could be cold palmitic acid or another fatty acid that does not affect the mobility of IPCb. The pathway proposed for the remodeling, involving the function of an IPC-acylhydrolase and an IPC-acyltransferase, is shown in Fig. 4A.

The compound labeled with [3H]inositol with the mobility of either lyosphosphatidylinositol (lyso-PI) or phosphatidylinositolmonophosphate (PIP) (indistinguishable in the plates, double bands c and d, in Fig. 2B) was eluted from the plate and treated with bacterial PI-PLC. Only IP, not IP2, could be detected by HPLC (Fig. 5), ruling out the presence of PIP.

PLA2 treatment of the lyso-PIs (c plus d), eluted from the plate shown in Fig. 2B, showed that only band c was affected, indicating that it was the 2-O-acyl derivative, formed by the action of an endogenous PLA2 on PI. When band d was subjected to saponification and butanol-water partition, the radioactivity was distributed between the two phases. The radioactivity in the aqueous phase corresponded to the 1-O-acyl-lyso-PI and that in the butanol phase corresponded to the 1-O-alkyl-lyso-PI, both originally formed by an endogenous PLA2 (Fig. 4B shows the possible pathway). A similar result was previously shown for epimastigotes (6).

The lyso-PIs are strongly labeled with [3H]inositol and only faintly labeled with [3H]palmitic acid, suggesting that remodeling of fatty acids is taking place in the PIa (Fig. 2A and B). Both precursors were also incorporated into the more polar GIPs (Fig. 2A and B). Their nature was confirmed by their
susceptibility to bacterial PI-PLC and analysis by TLC (data not shown). When [3H]inositol was used as the precursor, an increase in PI labeling occurred upon differentiation (Fig. 2B, lanes 8, 10, and 12), whereas there was no significant increase in labeling when [3H]palmitic acid was used, again indicating remodeling of the fatty acid in the PI, by the action of endogenous PLA and acyltransferase activities (Fig. 4B). The less polar lipids were labeled only with [3H]palmitic acid and corresponded to neutral lipids (Fig. 2A). The presence of free inositol (Fig. 2B) was confirmed by HPLC. The larger amount detected upon differentiation suggests either the action of a more active PI-PLC releasing IPs that are subsequently hydrolyzed by inositolphosphatases or a higher incorporation of inositol at low pH. To test if increased labeling of IPC and GIPLs in differentiating parasites was the result of a higher incorporation of inositol at pH 5, a control experiment was performed, in which the cells were labeled before their incubation at different pHs (Fig. 2C). Trypomastigotes were labeled with [3H]inositol for 4 h (lane 1, Fig. 2C), washed, and incubated for a further 5 h at either pH 7.5 (Fig. 2C, lane 2), or pH 5 (Fig. 2C, lane 3). No increase in labeling of IPCs above the increase observed when the cells were incubated at pH 7.5 (Fig. 2C, lane 2) was observed when cells were incubated at pH 5.0 (Fig. 2C, lane 3). In fact, a lower labeling of IPC was observed (Fig. 2C, lane 3), suggesting that the IPCs were used for the biosynthesis of GIPLs and that the differences shown in Fig. 2A and B were not due to increased incorporation of inositol at acidic pH.

FIG. 6. Phospholipases in T. cruzi amastigote and trypomastigote forms, active on PI and IPC. [3H]palmitic acid-labeled PI (A and B) and IPC (C and D) purified from T. cruzi epimastigotes were incubated for different times (5 min, lane 2; 15 min, lane 3; 1 h, lane 4; 2 h, lane 5; 18 h, lane 6) with a membrane fraction of amastigotes (A and C) or trypomastigotes (B and D). A supernatant of the membrane preparations was incubated for 18 h with the radioactive substrates (lane 7). A control consisting of the substrate incubated overnight with the buffer alone is shown in lane 1. A standard of [3H]palmitic acid is shown in lane 8. Incubations were performed with 250,000 cpm of substrate. After incubation the lipids were extracted as described under Materials and Methods and analyzed by TLC with solvent system B. The position of standards is indicated on the right. A, alkylglycerol; MAG, monoacylglycerol; C, ceramide. Characterization of compounds I to VI is described in Results.
Phospholipases in amastigotes and trypomastigotes active on PI. In order to confirm the presence of PI-PLC and PLA activities in membrane and soluble fractions of amastigote and trypomastigote forms of *T. cruzi*, we used radioactive IPLs as exogenous substrates. Thus, the IPLs from epimastigote forms of *T. cruzi*, metabolically labeled with [3H]palmitic acid, were separated into PI and IPC subfractions (8) and used to investigate these phospholipase activities. Figure 6 shows the results of incubation of [3H]PI with membranes of amastigotes (Fig. 6A, lanes 2 to 6) and trypomastigotes (Fig. 6B, lanes 2 to 6) for different times (5, 15, 60, and 120 min and 18 h). Also, the activity in the supernatant of the membrane preparation was analyzed in an overnight incubation (Fig. 6, lanes 7). After the indicated times, the lipids were extracted and analyzed by TLC with solvent B. The formation of less polar lipids than the IPLs was detected in all lanes except those corresponding to the controls, which were incubated in the buffer without membranes (Fig. 6A and B, lanes 1). The compounds of higher mobility (I, Fig. 6A and B) were eluted from the plates and chromatographed in solvent D (Fig. 7). Labeled 1,2-AAG and 1,2-di-O-palmitoylglycerol (DAG), produced by an endogenous PI-PLC, together with 1,3-AAG (see below), were detected after short incubation times (15 to 60 min, Fig. 7A, lane 1). The absence of radioactive 1,2-DAG after the 2-h incubation (Fig. 7A, lane 2) suggests that an acyltransferase activity introduced nonradioactive fatty acids after the action of a PLA₁ and a PLA₂ on the DAG of the labeled PI. This activity is reduced in trypomastigotes (Fig. 6B), as less monoacylglycerol (compound II) is formed during this incubation. The PI containing AAG is not a substrate for PLA₁. In fact, the total radioactivity of AAG does not change significantly with time (Fig. 7A). The intramolecular acyl migration observed in AAG (Fig. 7A) from position 2 to the more stable 1,3-isomer has been observed before (34).

The main degradation product in the incubation of radioactive PI with membranes of amastigotes and trypomastigotes was the fatty acid (compound III, Fig. 6A and B). The release of fatty acid was faster in amastigotes (5 min). After 15 min, most of the radioactive PI was degraded by amastigote membranes, but a considerable amount of PI still remained when it was incubated with equivalent amounts of trypomastigote membranes. Compound IV has the mobility of a lyso-PI generated by the endogenous PLA activities. For the identification of lipid IV (Fig. 6A and B) the samples eluted from the plate were treated with PLA₂ from *A. mellifera*. The release of fatty acid, as detected by TLC (data not shown), confirmed that a 2-O-acyl-glycerophosphoinositol is part of the lyso-PI and a substrate for the commercial PLA₂. The 2-O-acyl derivative originated from the action of an endogenous PLA₁ on the original DAG of the PI. Part of the lyso-PLs was not degraded by the PLA₂ treatment, suggesting that it was formed by an endogenous PLA₂ during incubation of PI with the membranes. In agreement with these results, treatment of [3H]-inositol-labeled lyso-PI, eluted from the plate shown in Fig. 2B (bands c and d), showed that only the upper band was a substrate for the commercial PLA₂ and confirmed the action of an endogenous PLA₁ on PI (Fig. 4B). The lysolipid, which was resistant to the commercial PLA₂, should be the product of the endogenous enzyme (data not shown). We also found that PI-PLC and PLA activities are present in a soluble fraction.
from amastigotes and trypomastigotes (Fig. 6A and B, lanes 7). In this regard, a lysosomal PLA₁ activity has been detected in *T. cruzi* with phosphatidylcholine as substrate (38), and PLA₁ and PLA₂ activities in epimastigote membranes have been previously reported (6).

**Phospholipases in amastigotes and trypomastigotes active on IPC.** To investigate IPC-phospholipase and fatty acid hydrolase activities, radioactive IPC was incubated with membrane and soluble fractions of amastigotes (Fig. 6C) and trypomastigotes (Fig. 6D). The compound of higher mobility (compound V; Fig. 6C and D) was identified as ceramide by elution and further analysis by TLC (Fig. 7B, lanes 2 and 3, respectively). This lipid is formed by an endogenous PI-PLC. The lipid released by incubation with a membrane fraction from epimastigotes is shown for comparison (Fig. 7B, lane 1). Fatty acid was also released by incubation of IPC with the membranes of amastigotes and trypomastigotes (band VI). However, the IPC-acylhydrolase activity was not soluble (Fig. 6C and D, lanes 7). The low amount of fatty acid detected after 18 h of incubation with the soluble fraction could originate from the contaminating PI present in the original sample of IPC.

**Effect of aureobasidin A on IPC and GIPL synthesis in differentiating trypomastigotes.** We also investigated whether the *T. cruzi* IPC synthesis was sensitive to aureobasidin A inhibition. Aureobasidin A inhibits the IPC synthase of *S. cerevisiae* (27), and it has been used to demonstrate that ceramides, which are introduced during remodeling of the GPI anchors, are not generated by the breakdown of IPCs but are newly synthesized (29). Differentiation of trypomastigotes in vitro was induced as described above in the presence of 5 μg of aureobasidin A/ml and [³H]inositol at either pH 7.5 (lanes 1, 3, 5, and 7) or pH 5.0 (lanes 2, 4, 6, and 8) in the presence of 0.5 (lanes 3 and 4), 2.5 (lanes 5 and 6), or 5.0 (lanes 7 and 8) μg of aureobasidin A/ml.

![Figure 8: Aureobasidin A inhibits the biosynthesis of IPC and GIPLs during differentiation of trypomastigotes in vitro.](http://ec.asm.org/)

**FIG. 8.** Aureobasidin A inhibits the biosynthesis of IPC and GIPLs during differentiation of trypomastigotes in vitro. (A) Differentiation in vitro was induced as described for Fig. 2. Trypomastigotes were incubated with [³H]inositol at pH 7.5 (lanes 1, 4, and 7) or at pH 5.0 (lanes 2, 3, 5, 6, 8, and 9). Lanes 3, 6, and 9 correspond to cells treated with 5 μg of aureobasidin A/ml during the differentiation. The same numbers of cells were extracted at different times: 2 h (lanes 1 to 3), 5 h (lanes 4 to 6), and 18 h (lanes 7 to 9). (B) Concentration-dependent inhibition of IPC and GIPL biosynthesis by aureobasidin A. Differentiation in vitro was induced as described for panel A. Trypomastigotes were incubated with [³H]inositol at either pH 7.5 (lanes 1, 3, 5, and 7) or pH 5.0 (lanes 2, 4, 6, and 8) in the presence of 0.5 (lanes 3 and 4), 2.5 (lanes 5 and 6), or 5.0 (lanes 7 and 8) μg of aureobasidin A/ml.
40 and 70% of the cells, respectively, had morphological characteristics of amastigotes (rounded and without a visible flagellum). Aureobasidin A decreased the percentage of amastigotes and increased the percentage of intermediate forms (“fat trypomastigotes”) in a dose- and time-dependent manner (Fig. 9). Immunofluorescence staining for the Ssp4 epitope (Fig. 10) revealed fewer cells expressing Ssp4 and more intermediate forms in aureobasidin A-treated preparations at acidic pH (Fig. 10B and C) compared with controls (Fig. 10A). When aureobasidin A was used at high concentrations, parasites maintained at acidic pH showed signs of toxicity (Fig. 10C). It is interesting that the IPC-acylhydrolase activity was not present in membranes of amastigotes and trypomastigotes (Fig. 6). This is better illustrated in the electron micrographs of Fig. 11. Aureobasidin A-treated differentiating parasites showed alterations in the Golgi apparatus as well as large lipidic vacuoles in close contact with the endoplasmic reticulum (Fig. 11B and C, arrowheads), while those maintained at pH 7.5 in the presence of aureobasidin A appeared normal (Fig. 11D and E). Most of the cells treated with aureobasidin A at pH 5.0 corresponded to intermediate forms; this was judged by the proximity of the kinetoplast to the nucleus, and the “basket-like” appearance of the kinetoplast in most cases, which is typical of trypomastigotes (13).

**DISCUSSION**

Differentiation of *T. cruzi* trypomastigotes to amastigotes inside myoblasts was accompanied by the formation of IPC, as revealed by the increased labeling of IPC detected in extracts from [3H]inositol-labeled myoblasts infected with trypomastigotes (Fig. 1A). When the differentiation occurred inside myoblasts labeled with [3H]palmitic acid, no radioactive IPC was detected (Fig. 1B). This result suggested that the ceramide in the IPC was not originating from the myoblasts but was probably of parasite origin. The inositol, however, was probably coming from the labeled pool of PI in the myoblasts, if synthesis in *T. cruzi* occurs as described for *S. cerevisiae* (29). In *S. cerevisiae* IPC is formed from PI by the action of an IPC synthase, which catalyzes the transfer of phosphorylinoisitol to ceramide (29). De novo synthesis of phosphorylinoisitol by the parasites with use of the free [3H]inositol available in the infected myoblasts cannot be ruled out, although it is not probable, since the amount of free inositol increased, rather than decreased, during differentiation (Fig. 1A). The Ssp4 surface glycoprotein that appears upon differentiation of trypomastigotes to amastigotes is known to be linked to a ceramide-GPI (7). Since a PI-PLC from *T. cruzi* is activated during differentiation (19) and is capable of cleaving IPC (31), it is possible that this ceramide could be used to synthesize the IPC that appears in the myoblasts after 18 h postinfection (Fig. 1A, lane 2). An IPC synthase has not been described and the biosynthetic pathway of IPC has not been elucidated in *T. cruzi*. No sequences with homology to *S. cerevisiae* IPC synthase have been found in searches of the currently available *T. cruzi* database (http://TcruziDB.org/) (data not shown).

The biosynthesis of IPC was also monitored during differentiation of trypomastigotes in vitro at low extracellular pH. In this case a different pattern was obtained when cells were labeled with [3H]palmitic acid or [3H]inositol. Two main IPCs were detected in differentiating trypomastigotes. The chemical nature of the IPCs in trypomastigotes was previously studied (37). When cells were labeled with [3H]inositol, it was evident that the levels of radioactive IPCs increased significantly during 6 h, in particular the less mobile IPC containing PS (Fig. 2B). However, when differentiating trypomastigotes were labeled with [3H]palmitic acid, labeling of IPCb greatly decreased with time (Fig. 2A, lanes 2, 4, and 6) while remaining at the same level in nondifferentiating trypomastigotes (Fig. 2A, lanes 1, 3, and 5). These results indicate that a remodeling step on the ceramide is taking place, with replacement of the N-linked radioactive fatty acid, particularly in the IPCb.

Evidence was found for the presence of an IPC-acylhydrolase in membranes of amastigotes and trypomastigotes (Fig. 6). It is interesting that the IPC-acylhydrolase activity was not soluble. As neither lysosphingolipid nor free sphingosine was formed, an IPC-acyltransferase introducing endogenous fatty acid should also be acting (Fig. 4). One enzyme could be responsible for both activities. In this regard, an enzyme which catalyzes the hydrolysis of ceramide, and also its synthesis in an...
acyl coenzyme A-independent manner, has been cloned from the mouse (35).

Remodeling of the fatty acids in the PIs, upon differentiation, was also evident (Fig. 2A and B) and in agreement with the presence of the enzyme activities detected in membranes and soluble fractions of both stages of the parasites (Fig. 6). The following results suggest that PLA activities remove radioactive fatty acids and are followed by PI acyltransferase activities that catalyze the transfer of cold fatty acids, thus leading to remodeled PI and lyso-PI (Fig. 4). (i) Labeling with \(^{3}H\)inositol of PI and lyso-PI increased with time of differentiation, whereas there was no increase in labeling of PI with \(^{3}H\)palmitic acid (Fig. 2A and B). (ii) Incubation of \(^{3}H\)palmitic acid-labeled PI with membranes of both stages of the parasite (Fig. 6A and B) showed much more release of radioactive fatty acid than of radioactive lyso-PI. It was previously shown that alkylglycerol, present in the major component of PI, is strongly labeled (6). Therefore, the lyso-PI formed after fatty acid removal should have been labeled to the same extent as the fatty acid unless transfer of a cold fatty acid had occurred. (iii) Analysis of the glycerolipids released by the endogenous PI-PLC after short incubation times (15 to 60 min) showed 1,2-AAG and 1,2-DAG (Fig. 7A, lane 1). However, no labeled 1,2-DAG was detected after 2 h (Fig. 7A, lane 2).

PI-PLC, as well as IPC-PLC, activities were found in the membrane and soluble fractions of amastigotes and trypomastigotes (Fig. 6). The PI-PLC previously cloned (19) could be responsible for these activities.

Cellular events regulated by ceramide have received growing attention in recent years (21, 22), among them induction of cell differentiation (22), a crucial step in \(T. cruzi\) infection. In vitro differentiation of trypomastigotes by external PI-PLC treatment has been reported (26). Our results suggest that IPC could fulfill a function similar to that of sphingolipids in mammalian cells by generating second messengers.

Activation of GIPPL biosynthesis upon differentiation to amastigotes was demonstrated (Fig. 2 and 8). The findings that glycerolipids were the main lipids in the GIPPLs detected in the early stages of differentiation, that ceramides were the major lipids after longer times of incubation, and that only ceramide has been found in the anchor of Ssp4 (7) points to a remodeling step for introduction of ceramide. In \(S. cerevisiae\), by using aureobasidin A, an inhibitor of IPC synthase, it was shown that the ceramide necessary for remodeling the GIPPLs linked to the protein is not generated by the breakdown of IPC.

FIG. 10. Effect of aureobasidin A on the morphology and expression of stage-specific epitope Ssp4. Trypomastigotes were induced to differentiate as described for Fig. 2. After 5 h, parasites were fixed and stained by immunofluorescence with monoclonal antibodies to Ssp4. (A) Control trypomastigotes incubated at pH 5.0 for 5 h; (B) trypomastigotes incubated at pH 5.0 with 10 \(\mu\)g of aureobasidin A/ml; (C) trypomastigotes incubated at pH 5.0 with 20 \(\mu\)g of aureobasidin A/ml. (D) trypomastigotes incubated at pH 7.5 with 20 \(\mu\)g of aureobasidin A/ml. Bars, 5 \(\mu\)m.
In the case of *T. cruzi* we also found inhibition of IPC synthesis by aureobasidin A, but in contrast to what occurs in yeast, the drug also inhibited the biosynthesis of GIPLs, suggesting that the ceramide used for remodeling is generated by the breakdown of IPC. On the other hand, in yeast ceramide is introduced only in the GIPLs already linked to the protein (28).

Aureobasidin A inhibited trypomastigote differentiation to amastigotes, leading to the increased appearance of intermediate forms and decreased expression of Ssp4. It has been reported previously (20) that heterologous expression of a *T. brucei* GPI-PLC in *T. cruzi* results in limited proliferation and inhibition of differentiation of amastigotes to trypomastigotes.

It was suggested that GPI-anchored proteins or free GIPLs of the parasites act as mediators for signals necessary for amastigote development (26). Taking into account our results, this could be related to the presence of ceramide in the GPI anchor of amastigote-specific glycoproteins. It is interesting that only trypomastigotes that were differentiating, not trypomastigotes maintained at neutral pH, showed signs of toxicity upon treatment with high concentrations of aureobasidin A. This would suggest that, like the PI-PLC (19), an IPC-synthesizing enzyme is induced upon differentiation. Inhibition of this enzyme in differentiating parasites would lead to accumulation of precursors such as ceramide that could be toxic to the cells. The IPC synthase, or an equivalent pathway, which is absent in mam-

---

**FIG. 11.** Effect of aureobasidin A on the ultrastructure of differentiating trypomastigotes. Trypomastigotes were induced to differentiate as described for Fig. 2. After 5 h, parasites were prepared for electron microscopy as described in Materials and Methods. (A) Control trypomastigotes incubated at pH 5.0 for 5 h; (B and C) trypomastigotes incubated at pH 5.0 with 10 μg of aureobasidin A/ml; (D and E) trypomastigotes incubated at pH 7.5 with 10 μg of aureobasidin A/ml. Abbreviations: n, nucleus; k, kinetoplast; g, Golgi apparatus; f, flagellum. Asterisks indicate lipid inclusions. Arrowheads show points of apparent contact between the lipid inclusions and the endoplasmic reticulum. Bars, 0.4 (A and B), 0.5 (C), 0.25 (D), and 0.6 (E) μm.
malian cells, could be therefore a good target for chemotherapy.

ACKNOWLEDGMENTS

We thank Norma W. Andrews for the monoclonal antibody to SpP4, David A. Scott for reading the manuscript, and Linda Brown for technical assistance.

This work was supported in part by grants from the American Heart Association, Midwest Affiliate, and the National Institutes of Health (AI-48039) (to S.N.J.M.) and from the University of Buenos Aires and Agencia Nacional de Promoción Científica y Tecnológica (PICT 06-05133) (to R.M.D.).

REFERENCES


EUKARYOT. CELL

Downloaded from http://ec.asm.org/ on October 24, 2017 by guest